Alvotech (ALVO)
| Market Cap | 1.02B -59.6% |
| Revenue (ttm) | 562.04M -4.4% |
| Net Income | -80.73M |
| EPS | -0.26 |
| Shares Out | 313.02M |
| PE Ratio | n/a |
| Forward PE | 90.75 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 469,973 |
| Open | 3.210 |
| Previous Close | 3.200 |
| Day's Range | 3.170 - 3.320 |
| 52-Week Range | 3.030 - 11.850 |
| Beta | 0.21 |
| Analysts | Buy |
| Price Target | 8.00 (+145.4%) |
| Earnings Date | May 6, 2026 |
About ALVO
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company provides AVT02, a high concentration, low-volume adalimumab formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, ankylosing spondylitis ulcerative colitis, and other indications; AVT04, a biosimilar to Stelara to treat variou... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for ALVO stock is "Buy." The 12-month stock price target is $8.0, which is an increase of 145.40% from the latest price.
News
Alvotech Earnings Call Transcript: Q1 2026
Q1 2026 saw revenues decline 20% year-over-year to $106 million due to facility improvements, but gross margin improved and EBITDA margin rose to 23%. Regulatory progress, new launches, and a strategic FUJIFILM partnership position the company for strong growth in 2027.
Alvotech Q1 2026 Financial Results
Alvotech (NASDAQ US: ALVO, ICELAND: ALVO, STOCKHOLM: ALVO SDB) Financial Highlights A supplemental long ‑ form earnings release providing additional operational details and business update for Q1 202...
Alvotech Announces a Change in its Executive Team
REYKJAVIK, ICELAND (April 30, 2026) — Alvotech (NASDAQ: ALVO, the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, ...
Alvotech to Report Financial Results for the First Quarter of 2026
REYKJAVIK, Iceland, April 24, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB) (the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar m...
Alvotech files Annual Report with the SEC
REYKJAVIK, ICELAND (March 30, 2026) — Alvotech (NASDAQ: ALVO) (the “Company”) has filed its Annual Report 2025 on Form 20-F for the financial year 2025 with the U.S. Securities and Exchange Commissio...
Alvotech Publishes 2025 Annual Report
REYKJAVIK, ICELAND (March 30, 2026) — Alvotech (NASDAQ: ALVO) (the “Company”) has published its Annual Report for 2025. The report is available in the investor relations section of Alvotech's website...
Alvotech price target lowered to $4 from $8 at Deutsche Bank
Deutsche Bank lowered the firm’s price target on Alvotech (ALVO) to $4 from $8 and keeps a Hold rating on the shares. The firm updated the company’s model post the
Alvotech price target lowered to $4 from $5 at Barclays
Barclays lowered the firm’s price target on Alvotech (ALVO) to $4 from $5 and keeps an Underweight rating on the shares. The firm expects the shares to “remain in a
Alvotech price target lowered to $6 from $10 at UBS
UBS lowered the firm’s price target on Alvotech (ALVO) to $6 from $10 and keeps a Buy rating on the shares. The firm is confident in the remediation plan outlined
Alvotech price target lowered to $4 from $5 at Barclays
Barclays lowered the firm’s price target on Alvotech (ALVO) to $4 from $5 and keeps an Underweight rating on the shares. While the firm remains bullish on the long-term outlook
Alvotech Earnings Call Transcript: Q4 2025
2025 saw 21% revenue growth to $593M and 27% higher adjusted EBITDA, driven by licensing and new launches. Guidance for 2026 is $650–$700M revenue, with U.S. launches providing upside. Regulatory remediation and expanded manufacturing underpin future growth.
Alvotech Q4 2025 and Full Year 2025 Financial Results
A supplemental long ‑ form earnings release providing additional operational details and business update for Q4 2025 and the full year is available at: https://investors.alvotech.com/earnings-calendar...
Alvotech to Report Fourth Quarter and Full Year 2025 Financial Results
REYKJAVIK, ICELAND (March 4, 2026) — Alvotech (NASDAQ: ALVO) (the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldw...
Alvotech Announces Increase in Number of Own Shares
REYKJAVIK, ICELAND (February 11, 2026) — Alvotech (NASDAQ: ALVO) (the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwi...
Alvotech Announces Positive Top-Line Results from Pivotal Pharmacokinetic Study for Proposed Biosimilar to Entyvio®
REYKJAVIK, ICELAND (February 5, 2026) – Alvotech (NASDAQ: ALVO), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announce...
Alvotech enters supply and commercialization agreements for Canada and Australia & New Zealand covering multiple biosimilar candidates
REYKJAVIK, ICELAND (February 2, 2026) — Alvotech (NASDAQ: ALVO), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today an...
Correction: Transactions of Managers and Closely Associated Persons
Attached are copies of two filings with the Luxembourg Commission de Surveillance du Secteur Financier (CSSF) regarding transactions of managers and closely associated persons. ATP Holdings ehf. annou...
Transactions of Managers and Closely Associated Persons
Attached is a copy of a filing with the Luxembourg Commission de Surveillance du Secteur Financier (CSSF) regarding transactions of managers and closely associated persons, announcing the acquisition ...
Alvotech CEO Robert Wessman to step down, Lisa Graver to succeed
Alvotech (ALVO) announced key senior leadership changes following a planned succession process. Founder Robert Wessman, who has served as Chairman since the company’s inception in 2013 and CEO since 2...
Alvotech Secures Term Loan Facility of USD 100 Million
REYKJAVIK, ICELAND (December 31, 2025) — Alvotech (NASDAQ: ALVO), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today a...
Changes in company's own shares
Attached is a filing with the Luxembourg Commission de Surveillance du Secteur Financier (CSSF) regarding changes in company's own shares. Attachment Alvotech Own Shares Notification 29 Dec 2025
Alvotech's Financial Calendar for 2026
Alvotech (NASDAQ: ALVO, ALVO SDB) today publishes its financial calendar for 2026. Annual or interim results are released on the dates specified below, after the close of U.S. markets. An investor cal...
Alvotech announces European launch of first-in-market biosimilar to Simponi® (golimumab) globally by partner Advanz Pharma
REYKJAVIK, Iceland, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients world...
Alvotech, Teva reach settlement and license agreement with Regeneron for AVT06
Alvotech (ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical (TEVA) announced that they have reached a settlement and license agreement with Regeneron (REGN) concerning the launch...
Alvotech Successfully Places USD 108 Million Senior Unsecured Convertible Bonds in a Significantly Oversubscribed Offering
THIS PRESS RELEASE MAY NOT BE DISTRIBUTED, RELEASED, OR PUBLISHED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH A...